USA Gilmore O’Neill, CEO of Editas Medicine, reflects on the company’s evolution from CRISPR pioneer to focused in vivo therapeutics developer. Two years into a strategic pivot, O’Neill shares the reasoning behind discontinuing the reni-cel cell therapy program in favor of lipid nanoparticle-delivered gene editing, and how EDIT-401, targeting severe hyperlipidemia,…
HIV Hopes have been raised of a cure for AIDS after a patient in London became free of the HIV virus following a bone marrow transplant. Although it is not a viable large-scale strategy for a cure … these new findings reaffirm our belief that there exists a proof of…
Pharma André Choulika, founder & CEO of Cellectis, reveals why the 21st century will be the century of gene editing and Cellectis will be one of the leaders of this revolution; how unlike many of their competitors, they are a gene editing company at the core and why the idea of…
See our Cookie Privacy Policy Here
